title: Tissue and serum galectin-1 expression in patients with colorectal carcinoma.
abstract: OBJECTIVE
  To observe the expressing model of galectin-1 in colorectal carcinoma (CRC) progress.
  
  
  METHODS
  The expression of galectin-1 in peritumor, adenoma and CRC tissues using immunohistochemistry, western-blotting and RT-PCR was detected. Serum galectin-1 concentrations were detected by ELISA.
  
  
  RESULTS
  Galectin-1 intensities in peritumor, adenoma and CRC tissues increased serially. Galectin- 1 expressed in the extracellular matrix of peritumor and pathological colorectal tissues mainly, while almost none was detected in colorectal epithelia. Different colorectal tissues expressed galectin-1 with different intensities. Non-parametric tests showed increased galectin-1 intensities were in peritumor, adenoma and carcinoma tissues (p<0.001). The over-expressing rates of galectin-1 in CRCs from Dukes A to D stage were increased significantly (p<0.001). Differently expressing intensities of galectin-1 were in different invasive locations of CRCs. RT-PCR showed that no statistically significant differences of galectin-1 mRNA were observed among peritumor colorectal tissue, adenoma and CRC tissues (p>0.05). Serum concentrations of galectin-1 decreased from healthy individuals to Dukes D CRCs. The differences between any of the groups were significant (p<0.05).
  
  
  CONCLUSIONS
  Stronger intensities of galectin-1 protein in the extracellular matrix of CRC tissues than those of peritumor and adenoma tissues, with no significant differences in the mRNA levels of galectin-1. Interestingly, serum galectin- 1 concentrations in patients with CRC decreased significantly. Above all, we presume that overexpression of galectin-1 protein in the CRCs is derived possibly from secreted galectin-1 from other normal tissues that cumulate in the stroma.
authors.affiliation: Guangzhou Military Command, Guangdong, China.
authors.forename: Tong-Hua
authors.initials: TH
authors.lastname: Sheng
authors.forename: Lai-Xiao
authors.initials: LX
authors.lastname: Rong
authors.forename: Zhang-Ya
authors.initials: ZY
authors.lastname: Li
authors.forename: Jiang
authors.initials: J
authors.lastname: Bo
authors.forename: Su
authors.initials: S
authors.lastname: Lei
mesh_terms: D000236:Adenoma / Q000097:blood / Q000737:chemistry* / Q000235:genetics; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood / Q000235:genetics; D015153:Blotting, Western; D002277:Carcinoma / Q000097:blood / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D015179:Colorectal Neoplasms / Q000097:blood / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells / Q000737:chemistry; D005260:Female; D037483:Galectin 1 / Q000032:analysis* / Q000097:blood / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017154:Stromal Cells / Q000737:chemistry; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D037483:Galectin 1; C445499:LGALS1 protein, human; D012333:RNA, Messenger